Translation from Finnish
Legally binding only in Finnish and Swedish
Ministry of Social Affairs and Health, Finland

Government Decree
on the amendment of Government Decree on the diseases regarded as severe and chronic on medical grounds, and the medicinal costs for which a 65 or 100 per cent reimbursement is made under Chapter 5, section 5(2) of the Health Insurance Act
(1149/2016)

The heading and sections 1 and 2 of the *Government Decree on the diseases regarded as severe and chronic on medical grounds, and the medicinal costs for which a 65 or 100 per cent reimbursement is made under chapter 5, section 5(2) of the Health Insurance Act* (25/2013) are amended as follows:

Government Decree on reimbursement of medical expenses due to severe and chronic diseases

Section 1

A 100% reimbursement of the reimbursement basis referred to in Chapter 5, section 9(1–3) of the Health Insurance Act (1224/2004) in excess of the fixed deductible laid down in chapter 5, section 5(2) of the Health Insurance Act is applied to the medicinal products that have either a replacement or remedial effect and which are indispensable for the treatment of the following diseases regarded as severe and chronic on medical grounds:

1. Anterior pituitary hypofunction
2. Diabetes insipidus
3. Diabetes, insulin-treated
4. Thyroid insufficiency
5. Adrenal cortical hypofunction
6. Hypoparathyroidism
7. Pernicious anaemia and other Vitamin B12 absorption disorders
8. Myasthenia gravis
9. Multiple sclerosis
10. Parkinson's disease and other comparable movement disorders
11. Epilepsy and comparable convulsive disorders
12. Severe psychotic and other severe mental disorders
13. Behavioural disorders associated with mental retardation
14. Glaucoma
15. Breast cancer
16. Prostate cancer

17. Leukemias and other malignant diseases of the blood and bone marrow as well as malignant diseases of the lymphatic system
18. Trigeminal neuralgia or neuralgia of the glossopharyngal nerve
19. Hypogammaglobulinemia
20. Severe hypofunction of sexual glands
21. Aplastic anaemia
22. Chronic disorders of Vitamin D metabolism
23. Congenital metabolic disorders
24. Chronic coagulation defects
25. Post-transplant conditions in organ or tissue transplants
26. Cancers of female genital organs
27. Idiopathic thrombocytopenia and granulocytopenia
28. Other malignant tumours
29. Sarcoidosis
30. Severe chronic pancreatic insufficiency
31. General erythroderma
32. Pemphigus
33. Uraemia requiring dialysis
34. Severe anaemia associated with chronic renal failure

Section 2

A 65% reimbursement of the reimbursement basis referred to in chapter 5, section 9(1–3) of the Health Insurance Act is applied to the medicinal products that are indispensable for the treatment of the following diseases regarded as severe and chronic on medical grounds:

1. Chronic cardiac insufficiency
2. Disseminated connective tissue diseases, rheumatoid arthritis and comparable conditions
3. Chronic asthma and similar chronic obstructive pulmonary disorders
4. Chronic hypertension
5. Chronic coronary heart disease
6. Chronic arrhythmias
7. Ulcerative colitis and Crohn's disease
8. Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia)
9. Gout
10. Dyslipidaemia associated with chronic coronary artery disease
11. Chronic and severe narcolepsy
12. Diabetes, non-insulin-treated

This Decree enters into force on January 1, 2017.